Drug Trial Radar · NCT03030157
Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma
Last checked: Nov 20, 2026Latest source record: Oct 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
220
Planned (sponsor's estimate)
Start
Jan 2017
Primary completion
Jan 2020
Study completion Jan 2020
Sponsor
- Lead sponsor
- RenJi HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai Pudong Hospital; Shanghai Pudong New Area Gongli Hospital
- First posted
- Jan 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Up to 30-40% of the patients may develop bladder recurrance after radical nephroureterectomy for primary upper tract urothelial carcinoma. Bladder tumor needs transurethral resection, which is associated with costs of treatment and potential poor prognosis. Although several randomized controlled trial have shown that prophylactic intravesical chemotherapy could prevent bladder tumor recurrence, the optimal schedule and duration of treatment are unkown. The investigators want to determine the efficiacy of single instillation versus long-term intravesical instillation of pirarubicin for bladder recurrence after radical nephrouretectomy for primary upper tract urothelial carcinoma.
Conditions
- Intravesical Instillation
Interventions
pirarubicin(THP)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of bladder cancer in the first 12 month following nephroureterectomyTime frame: 12 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renji Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.